Roman Cailleteau
Chief Medical Officer CORXEL Pharmaceuticals
Seminars
Thursday 16th July 2026
Engineering Small-Molecule Potency to Deliver Injectable-Strength Efficacy in a Scalable Daily Pill for Long-Term Treatment
1:40 pm
- Engineering next-generation small-molecule GLP-1 platforms to bypass the gastric proteolytic barrier, utilizing high-potency synthetic chemistry to deliver therapeutic concentrations that achieve weight-loss efficacy comparable to high-dose injectables (~9.7% reduction in 16 weeks) without the need for complex peptide absorption enhancers
- Implementing an “Oral-First” clinical strategy where patients bypass injectable induction entirely or transition to a long-term oral maintenance continuum, allowing companies to protect market share by offering highly tolerable, needle-free options for life-long weight stability and enhanced patient adherence
- Optimizing large-scale synthetic small-molecule manufacturing processes to bypass the global constraints of “cold-chain” distribution and specialized injection hardware, ensuring consistent drug availability to meet the projected 40%+ annual growth in global patient demand across U.S. and Asian markets
